News

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 30, 2020– Seres Therapeutics, Inc., (Nasdaq: MCRB) introduced at the moment that the Firm has accomplished enrollment of its SER-109 Section three scientific examine, ECOSPOR III. SER-109 is an oral, first-in-field microbiome therapeutic candidate that has been granted Orphan Drug and Breakthrough Remedy designations by the U.S. Meals and Drug Administration (FDA), and is being investigated to be used in stopping recurrent Clostridium difficile an infection (CDI).

“We’re happy to have achieved this critically vital company milestone. SER-109 has the potential to be the primary FDA-approved remedy for C. difficile an infection to deal with the underlying reason for this illness, and the primary authorized microbiome drug for any human situation. We consider SER-109 may basically rework the therapy of sufferers with recurrent C. difficile an infection, a life-altering infectious illness, and we eagerly look ahead to topline scientific outcomes in the course of this yr. With compelling Section three ECOSPOR III scientific information, we plan to have interaction in discussions with the FDA relating to a submitting for product approval,” stated Eric Shaff, President and Chief Government Officer of Seres. “We’re additionally working to advance our different promising scientific improvement candidates in gentle of the COVID-19 pandemic. This stays an evolving scenario and we’re rigorously reviewing our improvement plans to find out quickly advance our pipeline towards high-quality information readouts.”

SER-109 Examine Updates

The SER-109 Section three ECOSPOR III examine ( identifier: NCT03183128) is a multicenter, randomized, placebo-controlled examine which has enrolled 181 sufferers with multiply recurrent CDI up to now. ECOSPOR III had been designed to enroll 188 sufferers. The Firm has determined to halt enrollment on account of the COVID-19 pandemic. Seres believes that ECOSPOR III stays well-powered to guage the efficacy of SER-109. The ECOSPOR III examine’s main endpoint is the discount of CDI recurrence at as much as eight weeks following SER-109 administration, and the Firm expects to report examine ends in mid-2020 as had been deliberate.

Seres is grateful to the sufferers, principal investigators and scientific analysis groups who participated in ECOSPOR III, lots of whom at the moment are concerned within the battle towards COVID-19.

The SER-109 Section three ECOSPOR III examine consists of use of an goal Clostridium difficile cytotoxin assay to make sure that all sufferers getting into the examine have energetic CDI, in addition to to verify CDI recurrences through the examine (i.e., the ECOSPOR III main endpoint).

Seres plans to provoke a SER-109 Expanded Entry Program at chosen scientific websites collaborating within the ongoing Section three ECOSPOR III examine, and the Firm may provoke this system at extra scientific websites for eligible sufferers to have entry to SER-109.

Prior accomplished scientific research have demonstrated SER-109 bacterial engraftment into the gastrointestinal microbiome, and that engraftment is related to decreased recurrence of CDI. In all prior scientific research, SER-109 was related to a positive security profile.

The FDA has issued a number of security alerts associated to Fecal Microbiota Transplantation (FMT) and the chance of pathogen transmission together with warnings associated to Multi-Drug Resistant Organisms and SARS-CoV-2, the virus linked to COVID-19 (June 12, 2019Alert; March 12, 2020Alert; and March 23, 2020Alert). Unapproved FMT is broadly used underneath an FDA Enforcement Discretion coverage for the therapy of recurrent CDI that isn’t responsive to straightforward therapies.

In distinction to FMT, SER-109 is comprised of a extremely purified consortia of spore-based commensal micro organism and is manufactured underneath Good Manufacturing Practices (GMP) circumstances utilizing stringent requirements to make sure product high quality and consistency. Seres makes use of a novel manufacturing course of which has been demonstrated to inactivate quite a few potential pathogens, together with species of non-spore micro organism, similar to Escherichia coli, and viruses. The Firm’s manufacturing course of inactivates many rising potential pathogens the place diagnostic assays could not but be obtainable, similar to SARS-CoV-2. Seres has issued a place assertion highlighting the criticality of together with pathogen inactivation processes within the manufacture of microbiome therapeutics. Latest discussions with the FDA have indicated company assist relating to the elemental differentiation between FMT and Seres’ product candidates.

COVID-19 Impression and Different Scientific Program Updates

Seres continues to watch the influence of the COVID-19 pandemic on Firm operations and ongoing scientific improvement exercise, together with the SER-287 Section 2b examine in ulcerative colitis, the SER-401 Section 1b examine in metastatic melanoma, and SER-301, a rationally designed, fermented improvement candidate for ulcerative colitis. Mitigation actions to reduce COVID-19-related operation disruptions are ongoing; nonetheless, given the severity and evolving nature of the scenario, the timing of SER-287 Section 2b and SER-401 Section 1b scientific readouts is unsure. Seres doesn’t anticipate disruptions to the provision of its drug product candidates for ongoing research.

The SER-287 Section 2b examine is at present roughly 60% enrolled based mostly on the 201-patient goal examine dimension. SER-287 improvement exercise has been adversely impacted by a number of scientific websites halting non-essential procedures, together with endoscopies, which can make it tough to attain the unique enrollment goal in H2 2020 as deliberate. Seres is evaluating enrollment mitigation methods and attainable trial design modifications with the objective of acquiring a high-quality, clinically significant dataset inside a timeframe per Seres’ prior steering for its money runway extending into the second quarter of 2021. Moreover, the Firm is inspired by the FDA’s indications of flexibility in gentle of the COVID-19 pandemic, and plans to have interaction the FDA in discussions relating to any potential trial modifications.

Seres continues to execute on actions to advance SER-301 scientific improvement and the deliberate initiation of affected person dosing in Australia and New Zealand later this yr.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a number one microbiome therapeutics platform firm creating a novel class of organic medication which are designed to deal with illness by restoring the operate of a dysbiotic microbiome, the place the state of bacterial range and performance is imbalanced. Seres’ SER-287 program has obtained Quick Monitor and Orphan Drug designation from the U.S. Meals and Drug Administration and is being evaluated in a Section 2b examine in sufferers with energetic mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Remedy and Orphan Drug designations from the FDA and is in Section three improvement for recurrent C. difficile an infection. Seres can also be creating SER-401 in a Section 1b examine in sufferers with metastatic melanoma and SER-301 for ulcerative colitis. For extra info, please go to 

Ahead-Wanting Statements

This press launch incorporates forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995. All statements contained on this press launch that don’t relate to issues of historic reality ought to be thought-about forward-looking statements, together with statements regarding FDA approval of Seres’ therapeutic candidates, the timing and outcomes of ECOSPOR III and any of our different scientific research, the promise of microbiome therapeutics usually, the influence of the COVID-19 pandemic, the potential flexibility of the FDA with regard to our scientific trials, the anticipated minimal influence of the decreased trial dimension in ECOSPOR III, and the protection and purity of our product candidates. Any forward-looking statements signify administration’s opinions as of the date of this press launch. Whereas we could elect to replace such forward-looking statements in some unspecified time in the future sooner or later, we disclaim any obligation to take action, even when subsequent occasions trigger our views to alter. These forward-looking statements shouldn’t be relied upon as representing our views as of any date subsequent to the date of this press launch.

These forward-looking statements are based mostly on administration’s present expectations. These statements are neither guarantees nor ensures, however contain identified and unknown dangers, uncertainties and different vital elements that will trigger our precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements, together with, however not restricted to, the next: the unknown influence of COVID-19; we’ve incurred important losses, usually are not at present worthwhile and should by no means grow to be worthwhile; our want for extra funding; our unproven method to therapeutic intervention; our reliance on third events and collaborators to conduct our scientific trials, manufacture our product candidates and develop and commercialize our product candidates, if authorized; that we’ve no expertise manufacturing merchandise at industrial scale; our merchandise could grow to be topic to unfavorable pricing restrictions; we could face product legal responsibility lawsuits; we could face competitors from biosimilars; our potential to guard our commerce secrets and techniques and know-how; potential adjustments in U.S. patent regulation; and the chance of third get together lawsuits alleging we’re infringing on their mental property. These and different vital elements mentioned underneath the caption “Danger Elements” in our Annual Report on Kind 10-Okay filed with the Securities and Trade Fee, or SEC, on March 2, 2020 and our Present Report on Kind 8-Okay filed with the SEC on March 18, 2020, and our different studies filed with the SEC may trigger precise outcomes to vary materially from these indicated by the forward-looking statements made on this press launch. Any such forward-looking statements signify administration’s estimates as of the date of this press launch. Whereas we could elect to replace such forward-looking statements in some unspecified time in the future sooner or later, we disclaim any obligation to take action, even when subsequent occasions trigger our views to alter. These forward-looking statements shouldn’t be relied upon as representing our views as of any date subsequent to the date of this press launch.

Supply: Seres Therapeutics, Inc.
 

Posted: March 2020

Information Skilled Month-to-month Information Roundup – March 2020

Sarclisa Accredited to Deal with Sufferers with Advancing A number of Myeloma

A number of myeloma is an incurable blood most cancers that varieties within the bone marrow. This month, the U.S. Meals and Drug Administration (FDA) accredited Sanofi’s Sarclisa (isatuximab-irfc) utilized in mixture with pomalidomide and dexamethasone (pom-dex) for the remedy of adults with relapsed refractory a number of myeloma (RRMM). These sufferers have obtained at the least two prior therapies together with lenalidomide and a proteasome inhibitor.

Sarclisa is a monoclonal antibody that binds to the CD38 receptor on a number of myeloma cells. In medical research, Sarclisa added to pom-dex demonstrated a statistically vital enchancment in median development free survival (PFS) of 11.53 months in comparison with 6.47 months with pom-dex alone, in addition to a considerably better general response price. Sarclisa is given as an intravenous (IV) infusion together with pom-dex each week for 4 weeks after which each two weeks, till illness development or unacceptable toxicity.
The commonest unwanted side effects (> 20%) included neutropenia (96%), infusion-related reactions (39%), pneumonia (31%), higher respiratory tract an infection (57%) and diarrhea (26%). 

FDA Expands Epclusa Use in Youngsters with Hepatitis C Virus

Epclusa (sofosbuvir and velpatasvir) from Gilead Sciences is a protease inhibitor-free routine used for the remedy of power genotype 1-6 hepatitis C virus (HCV) an infection.

Epclusa is now indicated for the remedy of power HCV in sufferers as younger as 6 years of age or weighing at the least 17 kg, no matter HCV genotype or liver illness severity. Approval relies on knowledge from a Section 2, open-label trial that enrolled 175 youngsters who have been handled with Epclusa for 12 weeks. In youngsters 12 to <18 years outdated, remedy with Epclusa resulted in a remedy price (SVR12) of 93% (71/76) in these with genotype 1 HCV an infection and 100% in these with genotype 2, 3, four and 6 HCV an infection. In youngsters 6 to <12 years outdated, the SVR price was 93% (50/54) in these with genotype 1 HCV, 91% (10/11) in these with genotype Three HCV, and 100% in these with genotype 2 and four HCV an infection. Widespread unwanted side effects are headache and fatigue (in adults).

Allergan’s Durysta Implant Cleared for Glaucoma, Ocular Hypertension

Glaucoma causes injury to the optic nerve and can lead to irreversible imaginative and prescient loss and blindness. Durysta (bimatoprost implant) 10 mcg is biodegradable, prostaglandin analog ocular implant now FDA-approved for the discount of intraocular stress (IOP) in sufferers with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Approval relies on outcomes from Section Three ARTEMIS research evaluating 1,122 topics on the efficacy and security of Durysta versus twice every day topical timolol drops. In analysis research, Durysta diminished IOP by roughly 30% from baseline over the 12-weeks and met the predefined standards for non-inferiority to timolol drops. Durysta is given by way of intracameral administration instantly into the anterior chamber of the attention, and shouldn’t be re-administered to a watch that obtained prior Durysta. Conjunctival hyperemia was reported by 27% of sufferers, and international physique sensation, eye ache, photophobia, conjunctival hemorrhage and dry eye in 5% to 10% of sufferers, amongst different unwanted side effects.

Isturisa from Novartis OK’d for the Remedy of Cushing’s Illness

Cushing’s illness is a uncommon illness through which the adrenal glands make an excessive amount of of the hormone cortisol. An excessive amount of cortisol can result in well being points reminiscent of hypertension, weight problems, and kind 2 diabetes, amongst others.

In response, the FDA has accredited Novartis’ Isturisa (osilodrostat) oral tablets for adults with Cushing’s illness who both can’t endure pituitary gland surgical procedure or have undergone the surgical procedure however nonetheless have the illness. Isturisa is a cortisol synthesis inhibitor. In medical research on the finish of 24 weeks, about 50% of sufferers who obtained a dose starting from 2 mg twice a day to 30 mg twice a day had cortisol ranges inside regular limits. The commonest unwanted side effects reported have been adrenal insufficiency, headache, vomiting, nausea, fatigue and edema (swelling brought on by fluid retention).

Ofev: First Remedy for Group of Progressive Interstitial Lung Ailments

The FDA has accredited Boehringer Ingelheim’s Ofev (nintedanib) oral capsules to deal with sufferers with power fibrosing (scarring) interstitial lung illnesses (ILD) with a progressive phenotype (trait). It’s a first-time FDA-approval for this indication.

Approval was based mostly on knowledge from the INBUILD Section III research of 663 adults (imply age=66 years) with power fibrosing ILD with a progressive phenotype. Sufferers obtained 150 mg of Ofev twice a day or placebo. After 52 weeks, lung operate decline was slowed by 57% relative to placebo in those that obtained Ofev as measured by pressured very important capability, a typical lung operate take a look at. Essentially the most generally reported unwanted side effects of Ofev included diarrhea, nausea, abdomen ache, vomiting, liver issues, decreased urge for food, headache, and weight reduction. Ofev can also be accredited to deal with idiopathic pulmonary fibrosis and to gradual lung operate decline amongst sufferers with ILD related to systemic sclerosis or scleroderma.

Posted: March 2020

MONDAY, March 30, 2020 — Confronted with a looming scarcity of lifesaving ventilators, U.S. hospitals are scrambling for options and planning for the worst.

Intensive care items at besieged hospitals in New York and different cities are taking an “all palms on deck” strategy — recruiting medical doctors from varied specialties to assist deal with the inflow of severely ailing COVID-19 sufferers.

They’re additionally discovering methods to fill one other essential hole: A restricted provide of ventilators, machines that present respiratory assist to sufferers in respiratory misery.

Final week, the U.S. Meals and Drug Administration formally authorized one various to plain ventilators: anesthesia machines. The gear, usually used to place surgical procedure sufferers underneath, will be adjusted to supply oxygen to ICU sufferers.

“Anesthesia machines are ventilators. They’re just a bit totally different,” defined Dr. Lewis Kaplan, president of the Society of Vital Care Medication (SCCM).

It is the proper use for the gear, now sitting idle as elective surgical procedures are canceled, Kaplan mentioned.

Plus, he added, anesthesia machines can be found exterior of hospital partitions — at freestanding surgical procedure facilities, medical colleges and pharmaceutical labs.

“We’re leaving no stone unturned,” mentioned Kaplan, a surgical important care specialist on the College of Pennsylvania and VA Medical Middle in Philadelphia.

Presently, the USA has round 200,000 ventilators, the SCCM estimates. A lot of these are already in use, or are older, extra primary fashions that hospitals have readily available. The determine additionally consists of the federal authorities’s emergency stockpile.

Specialists have been warning the provision falls far wanting the anticipated demand. At a current webinar convened by the American Hospital Affiliation, one researcher projected that 960,000 Individuals may want a ventilator earlier than the pandemic is over.

In New York state, the epicenter of the nation’s outbreak, Gov. Andrew Cuomo has repeatedly mentioned hospitals there want at the least one other 30,000 ventilators. They’re bracing for circumstances to peak inside three weeks, when a projected 40,000 ventilators could also be wanted.

But it surely’s not solely ventilators which are briefly provide, Kaplan warned. There are too few well being care suppliers skilled in working them — work that’s usually carried out by ICU medical doctors, nurses and respiratory therapists with specialised coaching.

Hospitals are calling on different specialists with coaching in important care to assist, Kaplan mentioned — together with pulmonologists and anesthesiologists.

“Loads of our medical doctors are freed up from elective surgical procedures, and so they’re prepared to assist,” mentioned Dr. Mary Dale Peterson, president of the American Society of Anesthesiologists (ASA).

The SCCM is advising hospitals to strive “tiered” staffing plans, with ICU medical doctors as group leaders who oversee a number of non-ICU medical doctors with coaching in important care — who, in flip, oversee a fleet of different suppliers.

One other tactic, although controversial, was authorized by New York state on Thursday: permitting two sufferers to share one ventilator. NewYork-Presbyterian Hospital, in New York Metropolis, mentioned it had “applied a method that, in fastidiously chosen sufferers underneath the correct circumstances, allows a single mechanical ventilator to completely assist two sufferers concurrently.”

However the ASA, SCCM and different teams shortly got here out in opposition to the apply, saying it compromises sufferers’ security.

Peterson mentioned it is not potential to completely handle particular person sufferers’ wants when they’re sharing a ventilator. The best danger can be if one instantly deteriorates, and the steadiness of oxygen goes to the opposite.

Amid all of it, hospitals are additionally planning for the worst: rationing ventilators to sufferers most certainly to outlive.

Arthur Caplan heads the division of medical ethics at NYU Langone Well being in New York Metropolis. He mentioned the medical middle, like others, is devising insurance policies on the way to do it pretty.

“First, we attempt to save probably the most lives,” Caplan mentioned. He pressured that age alone wouldn’t be a deciding issue — however sufferers’ general situation and life expectancy are necessary concerns.

In an editorial printed final week within the New England Journal of Medication, a gaggle of main bioethicists laid out suggestions on honest allocation of “scarce sources.” One mentioned it’s “justifiable” to take away a affected person with a poor prognosis from a ventilator, to attempt to save one with higher survival odds.

Caplan agreed that such conditions might happen.

Some states, together with New York, New Jersey and Pennsylvania, are reportedly updating or creating tips on ventilator rationing. However Caplan predicted they will be “late,” as medical facilities decide on their very own insurance policies.

Equity — slightly than a “first-come, first-serve” state of affairs — is the purpose, in line with Caplan.

“It is good that we’re pondering this by means of,” he mentioned. “It is necessary that folks know it is not based mostly on age or revenue. [Ventilators] aren’t going to the wealthy or to celebrities.”

“I want we did not must plan for rationing,” Caplan added. “However we do.”

Regardless of the seriousness of the pandemic, everybody agreed that most of the people could make an important distinction in slowing the surge into hospitals.

“Take social distancing critically,” Peterson mentioned. “This is a matter of provide and demand, and we’ve to do every thing we are able to to mitigate the unfold of this illness.”

© 2020 HealthDay. All rights reserved.

Posted: March 2020

VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. ( CYDY), (“CytoDyn” or the “Firm”), a late-stage biotechnology firm creating leronlimab (PRO 140), a CCR5 antagonist with the potential for a number of therapeutic indications, introduced right this moment the three-day outcomes post-leronlimab therapy of the primary 4 sufferers below an Emergency Investigational New Drug (EIND) granted by the U.S. Meals and Drug Administration (FDA).  A complete of seven sufferers have been enrolled up to now below EIND in the identical main medical heart within the New York Metropolis space.

The therapy with leronlimab is focused as a remedy for sufferers who expertise respiratory issues on account of contracting SARS-CoV-2 inflicting the Coronavirus Illness 2019 (COVID-19).  Leronlimab is believed to supply therapeutic profit by enhancing the immune response whereas mitigating the “cytokine storm” that results in morbidity and mortality in these sufferers. 

Bruce Patterson, M.D., Chief Govt Officer and founding father of IncellDx, a diagnostic associate and advisor to CytoDyn, stated, “IncellDx has developed particular companion diagnostic checks to find out the efficacy and dosing of leronlimab in these extreme circumstances of COVID-19. We discovered that sufferers with extreme COVID-19 illness are within the midst of immunologic chaos which incorporates the cytokine storm. Our companion diagnostics confirmed that after three days of remedy, the immune profile in these sufferers approached regular ranges and the degrees of cytokines concerned within the cytokine storm have been a lot improved.”

Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, “These preliminary outcomes give hope that leronlimab could assist hospitalized sufferers with COVID-19 recuperate from the pulmonary irritation that drives mortality and the necessity for ventilators. A number one medical heart within the coronary heart of the New York Metropolis epidemic was instrumental in giving the preliminary information.”

Nader Pourhassan, Ph.D., President and Chief Govt Officer of CytoDyn stated: “We’re extraordinarily happy for the coronavirus sufferers below the care of the treating medical workforce and that the FDA is so conscious of advance our Section 2 medical trial. I’m very hopeful that leronlimab might help to scale back the speed of mortality amongst COVID-19 sufferers with extreme signs of ARDS and to help our authorities to struggle this battle.”

About Coronavirus Illness 2019

SARS-CoV-2 was recognized as the reason for an outbreak of respiratory sickness first detected in Wuhan, China. The origin of SARS-CoV-2 inflicting the COVID-19 illness is unsure, and the virus is very contagious. COVID-19 usually transmits individual to individual via respiratory droplets, generally ensuing from coughing, sneezing, and shut private contact. Coronaviruses are a big household of viruses, some inflicting sickness in folks and others that flow into amongst animals. For confirmed COVID-19 infections, signs have included fever, cough, and shortness of breath. The signs of COVID-19 could seem in as few as two days or so long as 14 days after publicity. Medical manifestations in sufferers have ranged from non-existent to extreme and deadly. Presently, there are minimal therapy choices for COVID-19.

About Leronlimab (PRO 140)

The FDA has granted a “Quick Monitor” designation to CytoDyn for 2 potential indications of leronlimab for lethal illnesses. The primary as a mixture remedy with HAART for HIV-infected sufferers and the second is for metastatic triple-negative breast most cancers. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a mobile receptor that’s essential in HIV an infection, tumor metastases, and different illnesses, together with NASH. Leronlimab has accomplished 9 medical trials in over 800 folks, together with assembly its major endpoints in a pivotal Section three trial (leronlimab together with customary antiretroviral therapies in HIV-infected treatment-experienced sufferers).

Within the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus defending wholesome T cells from viral an infection by blocking the predominant HIV (R5) subtype from getting into these cells. Leronlimab has been the topic of 9 medical trials, every of which demonstrated that leronlimab may considerably scale back or management HIV viral load in people. The leronlimab antibody seems to be a strong antiviral agent resulting in doubtlessly fewer uncomfortable side effects and fewer frequent dosing necessities in contrast with day by day drug therapies presently in use.

Within the setting of most cancers, analysis has proven that CCR5 could play a job in tumor invasion, metastases, and tumor microenvironment management. Elevated CCR5 expression is an indicator of illness standing in a number of cancers. Revealed research have proven that blocking CCR5 can scale back tumor metastases in laboratory and animal fashions of aggressive breast and prostate most cancers. Leronlimab lowered human breast most cancers metastasis by greater than 98% in a murine xenograft mannequin. CytoDyn is, subsequently, conducting a Section 1b/2 human medical trial in metastatic triple-negative breast most cancers and was granted Quick Monitor designation in Could 2019. 

The CCR5 receptor seems to play a central function in modulating immune cell trafficking to websites of irritation. It might be essential within the growth of acute graft-versus-host illness (GvHD) and different inflammatory circumstances. Medical research by others additional help the idea that blocking CCR5 utilizing a chemical inhibitor can scale back the medical influence of acute GvHD with out considerably affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is presently conducting a Section 2 medical examine with leronlimab to help additional the idea that the CCR5 receptor on engrafted cells is vital for the event of acute GvHD, blocking the CCR5 receptor from recognizing particular immune signaling molecules is a viable strategy to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.

About CytoDyn

CytoDyn is a late-stage biotechnology firm creating revolutionary therapies for a number of therapeutic indications primarily based on leronlimab, a novel humanized monoclonal antibody focusing on the CCR5 receptor. CCR5 seems to play a vital function within the capability of HIV to enter and infect wholesome T-cells. The CCR5 receptor additionally seems to be implicated in tumor metastasis and immune-mediated diseases, akin to GvHD and NASH. CytoDyn has efficiently accomplished a Section three pivotal trial with leronlimab together with customary antiretroviral therapies in HIV-infected treatment-experienced sufferers. CytoDyn plans to hunt FDA approval for leronlimab together remedy and plans to finish the submitting of a Biologics License Software (BLA) within the first quarter of 2020 for that indication. CytoDyn can be conducting a Section three investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected sufferers. CytoDyn plans to provoke a registration-directed examine of leronlimab monotherapy indication. If profitable, it may help a label extension. Medical outcomes so far from a number of trials have proven that leronlimab can considerably scale back viral burden in folks contaminated with HIV with no reported drug-related critical antagonistic occasions (SAEs). Furthermore, a Section 2b medical trial demonstrated that leronlimab monotherapy can forestall viral escape in HIV-infected sufferers; some sufferers on leronlimab monotherapy have remained virally suppressed for greater than 5 years. CytoDyn can be conducting a Section 2 trial to guage leronlimab for the prevention of GvHD and a Section 1b/2 medical trial with leronlimab in metastatic triple-negative breast most cancers. Extra data is at

Ahead-Wanting Statements 
This press launch accommodates sure forward-looking statements that contain dangers, uncertainties and assumptions which might be troublesome to foretell.  Phrases and expressions reflecting optimism, satisfaction or disappointment with present prospects, in addition to phrases akin to “believes,” “hopes,” “intends,” “estimates,” “expects,” “tasks,” “plans,” “anticipates” and variations thereof, or the usage of future tense, determine forward-looking statements, however their absence doesn’t imply {that a} assertion isn’t forward-looking. The Firm’s forward-looking statements are usually not ensures of efficiency, and precise outcomes may fluctuate materially from these contained in or expressed by such statements as a result of dangers and uncertainties together with: (i) the sufficiency of the Firm’s money place, (ii) the Firm’s capability to lift extra capital to fund its operations, (iii) the Firm’s capability to satisfy its debt obligations, if any, (iv) the Firm’s capability to enter into partnership or licensing preparations with third events, (v) the Firm’s capability to determine sufferers to enroll in its medical trials in a well timed vogue, (vi) the Firm’s capability to attain approval of a marketable product, (vii) the design, implementation and conduct of the Firm’s medical trials, (viii) the outcomes of the Firm’s medical trials, together with the potential of unfavorable medical trial outcomes, (ix) the marketplace for, and marketability of, any product that’s accredited, (x) the existence or growth of vaccines, medication, or different therapies which might be considered by medical professionals or sufferers as superior to the Firm’s merchandise, (xi) regulatory initiatives, compliance with governmental laws and the regulatory approval course of, (xii) basic financial and enterprise circumstances, (xiii) modifications in overseas, political, and social circumstances, and (xiv) numerous different issues, a lot of that are past the Firm’s management. The Firm urges buyers to contemplate particularly the varied threat components recognized in its most up-to-date Type 10-Okay, and any threat components or cautionary statements included in any subsequent Type 10-Q or Type 8-Okay, filed with the Securities and Change Fee. Besides as required by legislation, the Firm doesn’t undertake any duty to replace any forward-looking statements to consider occasions or circumstances that happen after the date of this press launch.

Supply: CytoDyn Inc.

Posted: March 2020

Leronlimab FDA Approval Historical past

FRIDAY, March 27, 2020 — Prenatal and perinatal elements could affect a baby’s threat for growing psychosis, in accordance with a overview and meta-analysis printed on-line March 24 in The Lancet Psychiatry.

Cathy Davies, Ph.D., from King’s Faculty London, and colleagues performed a scientific literature overview to determine research evaluating the affiliation between prenatal or perinatal threat and protecting elements and psychotic issues.

The researchers recognized 152 eligible research evaluating 98 threat or protecting elements. Vital threat elements had been: maternal age <20 years (odds ratio [OR], 1.17) or 30 to 34 years (OR, 1.05); paternal age <20 years (OR, 1.31) and >35 years (OR, 1.28); any maternal (OR, 4.60) or paternal (OR, 2.73) psychopathology; maternal psychosis (OR, 7.61) and affective dysfunction (OR, 2.26); three or extra pregnancies (OR, 1.30); herpes simplex 2 (OR, 1.35); maternal infections not in any other case specified (NOS; OR, 1.27); suboptimal variety of antenatal visits (OR, 1.83); winter (OR, 1.05) and winter to spring (OR, 1.05) season of beginning within the northern hemisphere; maternal stress NOS (OR, 2.40); any famine or dietary deficits in being pregnant (OR, 1.40); maternal hypertension (OR, 1.40); hypoxia (OR, 1.63); ruptured (OR, 1.86) and untimely rupture (OR, 2.29) of membranes; polyhydramnios (OR, 3.05); particular obstetric problems NOS (OR, 1.83); birthweights <2,000 g (OR, 1.84), <2,500 g (OR 153), or 2,500 to 2,999 g (OR, 1.23); beginning size <49 cm (OR, 1.17); small for gestational age (OR, 1.40); untimely beginning (OR, 1.35); and congenital malformations (OR, 2.35). Vital protecting elements had been fewer and included maternal ages 20 to 24 years (OR, 0.93) and 25 to 29 years (OR, 0.92); nulliparity (OR, 0.91); and birthweights 3,500 to three,999 g (OR, 0.90) or >4,000 g (OR, 0.86).

“The up to date information rising from this research may refine understanding of psychosis pathogenesis, improve multivariable threat prediction, and inform preventive methods,” the authors write.

One creator disclosed ties to a pharmaceutical firm.

Summary/Full Textual content (subscription or cost could also be required)
Editorial (subscription or cost could also be required)

© 2020 HealthDay. All rights reserved.

Posted: March 2020

SATURDAY, March 28, 2020 — President Donald Trump signed a $2 trillion financial stimulus bundle into regulation on Friday, as U.S. coronavirus instances surged previous 100,000 and the loss of life toll handed 1,600.

The unprecedented laws will ship $1,200 to hundreds of thousands of Individuals, together with these incomes as much as $75,000, together with $500 per youngster. It is going to additionally give a further 13 weeks in unemployment support and a four-month enhancement of jobless advantages, The New York Occasions reported.

The bundle additionally consists of $377 billion in federally assured loans to small companies and the creation of a $500 billion authorities lending program for distressed firms. Hospitals on the entrance strains of the pandemic may even get $100 billion in support, the Occasions reported.

Additionally on Friday, Trump issued an order to pressure Basic Motors to fabricate ventilators, the Occasions reported. The motion represented an about-face after he had largely dismissed the outcry for ventilators earlier within the day. As well as, he signed an order on Friday that allows the Pentagon to convey former troops again to energetic responsibility to assist with the army’s response to the pandemic.

All the assist comes not a second too quickly, as greater than 100 million Individuals have been ordered by their state’s governors to remain dwelling.

New York is the epicenter of the U.S. outbreak, with greater than 44,635 instances and 535 deaths, in response to the Occasions.

“We’re in for a bumpy trip for the subsequent 12 to 18 months,” Dr. Ashish Jha, the director of the Harvard International Well being Institute, informed CNN. “If we’re aggressive now about stopping issues, shutting down, build up a check regime, we will then open up once more … and most locations can return to work. However solely after we are prepared. And we’re nowhere close to prepared now.”

Regardless of the steep rise in U.S. instances and dire projections, Trump has stated he wish to re-open the nation by Easter, April 12, the Occasions reported.

On Thursday, Trump tailor-made his message barely, suggesting that strict social distancing measures is perhaps eased quickly in elements of the nation the place the virus is just not spreading extensively.

Most well being consultants have reacted negatively to Trump’s plan, nonetheless.

If persons are informed they’ll head again to work, commuting by bus or subway whereas 1000’s of recent infections are confirmed every day, “the virus will surge, many will fall unwell and there can be extra deaths,” Dr. William Schaffner, a preventive drugs professional at Vanderbilt College’s College of Drugs, in Nashville, informed the Occasions.

Trump’s remarks additionally got here in sharp distinction to actions different leaders have taken world wide this previous week: India ordered a 21-day shutdown of a rustic by which 1.Three billion folks reside, whereas Japan’s Prime Minister Shinzo Abe and Worldwide Olympic Committee (IOC) president Thomas Bach agreed to postpone the Summer time Olympics in that nation till at the very least the summer time of 2021.

The UK has additionally ordered a shutdown of its nation, whereas Prince Charles, the 71-year-old inheritor to the British throne, was recognized with coronavirus on Wednesday, CNN reported. Prime Minister Boris Johnson was additionally recognized with COVID-19 on Friday, the primary head of state to take action, CNN reported.

Grim statistics pile up within the U.S.

Issues are notably dire in New York Metropolis, the place one hospital in Queens noticed 13 COVID-19 deaths in 24 hours, the Occasions reported.

Citywide, all the greater than 1,800 intensive care beds had been anticipated to be full by the weekend, in response to a Federal Emergency Administration Company briefing memo obtained by the Occasions.

New York Governor Andrew Cuomo did supply up some excellent news on Wednesday, saying that social distancing measures is perhaps working. This week, the state’s hospitalization estimations had been down markedly, from a doubling of instances each two days to a doubling each 4 days.

And in New Rochelle, N.Y., drastic measures to comprise a cluster there seemed to be paying off by Friday with a slowing in new instances, the Occasions reported.

However instances are simply beginning to spike elsewhere, notably within the South: Louisiana, Florida and Georgia are dealing with alarming will increase, with greater than 4,700 instances and 125 deaths reported in these three states alone, CBS Information reported Friday.

New Orleans now has extra instances than Los Angeles County, which is 25 instances bigger, CBS Information reported.

Sizzling spots, and areas comparatively untouched

And a few well being officers are warning that elements of Michigan and Illinois may very well be the subsequent epicenters of the coronavirus pandemic, CNN reported.

Dr. Deborah Birx, the White Home’s coronavirus response coordinator, stated Thursday that well being officers are involved that counties like Wayne County, Mich., and Prepare dinner County, Ailing., are exhibiting a “extra speedy enhance” in instances.

Nonetheless, Birx additionally famous that 40% of the nation has “extraordinary low charges of coronavirus,” with roughly 19 states reporting fewer than 200 instances, CNN reported.

Together with Cuomo, at the very least 21 different governors have introduced stay-at-home orders in states together with California, Illinois, Louisiana, Ohio, Oregon, Washington state and Hawaii, CNN reported.

Financial assist, medical provides coming

Earlier this month, Trump accredited catastrophe declarations for areas hit hardest by the pandemic, activating the Nationwide Guard in three states.

The declarations will convey provides, medical stations and naval hospital ships to New York, Washington state and California, CNN reported.

As international locations world wide surprise what’s in retailer for his or her residents within the coming months, one glimmer of hope has emerged: On Tuesday, China lifted journey restrictions on the Hubei province, which was hardest hit by coronavirus earlier this yr. On Saturday, China will start a ban on overseas vacationers to its nation, to keep away from potential re-infections there, the Related Press stated.

The excellent news in China stood in sharp aid to what’s unfolding in Italy.

On Saturday, Italy handed China for coronavirus instances, reporting greater than 86,000 and over 9,000 deaths, the AP reported. The virus has been particularly lethal for older Italians. However the nation has seen a slowing within the fee of recent infections for the fourth day in a row, the Occasions reported.

State, native officers proceed shutdowns

In the meantime, state and native officers throughout the USA continued to order the momentary closings of bars, nightclubs and eating places.

Final week, the Trump administration ramped up its coronavirus “social distancing” advisory to now discourage gatherings of 10 or extra folks.

Along with advising towards group gatherings of greater than 10 folks, Trump additionally discouraged consuming and consuming at eating places, bars and meals courts, and any discretionary journey.

The president additionally stated his administration is doubling down on testing for COVID-19. Shops similar to Walmart, CVS and Walgreens have put aside a part of their parking heaps for drive-through testing.

States race to comprise virus

Within the meantime, the general public lives of Individuals have come to a halt, because the coronavirus pandemic has prompted officers throughout the nation to shut, cancel or postpone any occasion or exercise that may foster the unfold of COVID-19.

New York, Washington state and California have been exhausting hit by coronavirus instances in the USA. New York has 44,635 instances, Washington state has 3,770 instances and California has 4,914, in response to the Occasions.

A surge of coronavirus instances in California has begun and can worsen, Gov. Gavin Newsom stated Friday, the AP reported, whereas the mayor of Los Angeles warned that his metropolis may quickly see the sort of hospital crush that has crippled New York Metropolis.

“We at the moment are seeing the spike that we had been anticipating,” Newsom declared whereas standing in entrance of the 1,000-bed Navy hospital ship Mercy that arrived within the Port of Los Angeles on Friday. It is going to take non-virus sufferers to release rooms at hospitals for coronavirus instances.

In the meantime, officers in Florida have closed most seashores within the state after younger spring breakers ignored social distancing pointers and partied with abandon on the sand. And on Friday, Gov. Ron DeSantis put a two-week halt on any new trip leases and ordered state troopers to cease drivers from Louisiana to inform them to self-isolate for 14 days. Florida now has 3,198 instances, with 46 deaths.

Worldwide, the case rely approached 620,000 whereas the loss of life toll topped 28,000 on Saturday, in response to a operating rely stored by Johns Hopkins College.

© 2020 HealthDay. All rights reserved.

Posted: March 2020

NEW BRUNSWICK, N.J., March 13, 2020 – Johnson & Johnson right now introduced that its Janssen Pharmaceutical Corporations have entered a collaboration with the Beth Israel Deaconess Medical Heart (BIDMC) to help the event of a preventive vaccine candidate for COVID-19. The events have commenced preclinical testing of a number of vaccine prospects, with the goal to establish by the tip of the month a COVID-19 vaccine candidate for scientific trials.

Janssen is optimistic that, in collaboration with a number of world strategic companions, it will probably provoke a Section 1 scientific research of a possible vaccine candidate by the tip of the yr. In parallel to those efforts, Janssen is making ready to upscale manufacturing and manufacturing capacities to ranges required to fulfill world public well being vaccination wants.

“It’s vital to work with one of the best scientific minds as we glance to quickly establish and develop options to the COVID-19 outbreak,” stated Paul Stoffels, M.D., Vice Chairman of the Govt Committee and Chief Scientific Officer, Johnson & Johnson. “We’re grateful for proficient and skilled collaboration companions like Dan Barouch and his workforce at BIDMC. By mobilizing our collective assets, we imagine we will leverage the highest science and cutting-edge capabilities to reply to this pandemic.”

Janssen’s vaccine program will use the Janssen AdVac® and PER.C6® applied sciences that present the power to quickly upscale manufacturing of an optimum vaccine candidate. The corporate is leveraging its confirmed vaccine know-how that it is usually utilizing to develop its investigational Ebola (which additionally makes use of its MVA-BN® know-how), Zika, RSV and HIV vaccines. Analysis and collaboration on preclinical work for our Zika and HIV vaccine candidates on the Heart for Virology and Vaccine Analysis at Beth Israel Deaconess Medical Heart was foundational to creating these vaccines.

Dan Barouch, M.D., Ph.D., Director of the Heart for Virology and Vaccine Analysis at BIDMC and the Ragon Institute, said, “We’re presently evaluating a collection of potential vaccine candidates for COVID-19. This collaboration with Janssen is aimed on the improvement of a COVID-19 vaccine that will permit for fast improvement, large-scale manufacturing, and world supply.”

Dr. Barouch’s workforce is well-known for his or her work on the pathogenesis and immunology of viral infections and the event of vaccine methods for world infectious ailments.

Johnson & Johnson’s efforts to expedite improvement and manufacturing of a vaccine are enhanced by the prevailing COVID-19 vaccine collaborations between Janssen and the Biomedical Superior Analysis and Growth Authority (BARDA), a part of the Workplace of the Assistant Secretary for Preparedness and Response (ASPR) on the U.S. Division of Well being & Human Providers.

Along with Janssen’s efforts to develop a vaccine candidate, the Firm is working carefully with world strategic companions to display screen its library of antiviral molecules to speed up the invention of potential COVID-19 therapies and supply reduction for individuals around the globe.

For extra info on Johnson & Johnson’s multipronged response to figuring out vital options to the COVID-19 outbreak, please go to: 

About Johnson & Johnson

At Johnson & Johnson, we imagine good well being is the muse of vibrant lives, thriving communities and ahead progress. That’s why for greater than 130 years, now we have aimed to maintain individuals effectively at all ages and each stage of life. At the moment, because the world’s largest and most broadly-based healthcare firm, we’re dedicated to utilizing our attain and dimension for good. We attempt to enhance entry and affordability, create more healthy communities, and put a wholesome thoughts, physique and atmosphere inside attain of everybody, all over the place. We’re mixing our coronary heart, science and ingenuity to profoundly change the trajectory of well being for humanity. Be taught extra at Comply with us at @JNJNews.

In regards to the Janssen Pharmaceutical Corporations

At Janssen, we’re making a future the place illness is a factor of the previous. We are the Pharmaceutical Corporations of Johnson & Johnson, working tirelessly to make that future a actuality for sufferers all over the place by preventing illness with science, enhancing entry with ingenuity, and therapeutic hopelessness with coronary heart. We give attention to areas of medication the place we will make the largest distinction: Cardiovascular & Metabolism, Immunology, Infectious Illnesses & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Be taught extra at Comply with us at @JanssenGlobal.

Discover to Traders Regarding Ahead-Trying Statements
This press launch comprises “forward-looking statements” as outlined within the Non-public Securities Litigation Reform Act of 1995 concerning darunavir/cobicistat and improvement of potential preventive and remedy regimens for COVID-19. The reader is cautioned to not depend on these forward-looking statements. These statements are primarily based on present expectations of future occasions. If underlying assumptions show inaccurate or identified or unknown dangers or uncertainties materialize, precise outcomes may differ materially from the expectations and projections of the Janssen Pharmaceutical Corporations and/or Johnson & Johnson. Dangers and uncertainties embrace, however should not restricted to: challenges and uncertainties inherent in product analysis and improvement, together with the uncertainty of scientific success and of acquiring regulatory approvals; uncertainty of economic success; manufacturing difficulties and delays; competitors, together with technological advances, new merchandise and patents attained by rivals; challenges to patents; product efficacy or security issues leading to product remembers or regulatory motion; modifications in habits and spending patterns of purchasers of well being care services; modifications to relevant legal guidelines and laws, together with world well being care reforms; and traits towards well being care value containment. An extra record and descriptions of those dangers, uncertainties and different components could be present in Johnson & Johnson’s Annual Report on Kind 10-Okay for the fiscal yr ended December 29, 2019, together with within the sections captioned “Cautionary Observe Relating to Ahead-Trying Statements” and “Merchandise 1A. Threat Components,” and within the firm’s most not too long ago filed Quarterly Report on Kind 10-Q, and the corporate’s subsequent filings with the Securities and Alternate Fee. Copies of those filings can be found on-line at , or on request from Johnson & Johnson. Not one of the Janssen Pharmaceutical Corporations nor Johnson & Johnson undertakes to replace any forward-looking assertion because of new info or future occasions or developments.

Supply: Johnson & Johnson

Posted: March 2020

Information Skilled Average Maternal Fish Consumption Could Assist Baby Metabolic Well being

FRIDAY, March 27, 2020 — Average fish consumption throughout being pregnant (one to 3 instances per week) is related to enhancements within the subsequent metabolic well being of kids, in line with a research printed on-line March 16 in JAMA Community Open.

Nikos Stratakis, Ph.D., from the College of Southern California in Los Angeles, and colleagues used meals questionnaire information from the Human Early Life Exposome venture (April 1, 2003, to Feb. 26, 2016). Maternal mercury focus was assessed utilizing entire blood and twine blood samples. The evaluation included 805 moms and their singleton offspring (follow-up till the youngsters have been aged 6 to 12 years) in 5 European international locations (France, Greece, Norway, Spain, and the UK).

The researchers discovered that fish consumption per well being suggestions (one to 3 instances per week) throughout being pregnant was related to a 1-U lower within the metabolic syndrome rating in kids (β = −0.96) in contrast with low fish consumption (lower than as soon as every week) after adjusting for maternal mercury ranges and different covariates. There was no additional profit with fish consumption of greater than 3 times per week. There was an unbiased affiliation seen between a rise within the metabolic syndrome rating of offspring and better maternal mercury focus (β per twofold improve in mercury focus = 0.18). Average and excessive fish consumption throughout being pregnant have been related to decreased ranges of proinflammatory cytokines and adipokines in kids versus low fish consumption.

“Our outcomes recommend that, for pregnant ladies, the good thing about fish consumption that’s per suggestions from the U.S. Meals and Drug Administration and the Environmental Safety Company exceeds the chance by way of the metabolic well being of kids,” the authors write.

Summary/Full Textual content

© 2020 HealthDay. All rights reserved.

Posted: March 2020

FRIDAY, March 27, 2020 — Electrical vehicles actually are greener than gasoline ones, researchers report.

Some have questioned whether or not electrical vehicles may really enhance carbon emissions when the era of the electrical energy to run them is taken into consideration.

However a brand new examine concluded that in most areas of the world, electrical vehicles scale back carbon emissions general, even when the era of electrical energy to energy them makes use of substantial quantities of fossil gas.

“The reply is obvious: to scale back carbon emissions, we must always select electrical vehicles … over fossil-fuel options,” stated examine lead writer Florian Knobloch, from the Environmental Science Division at Radboud College within the Netherlands.

At present, electrical vehicles are higher for the local weather than gasoline vehicles in 95% of nations, based on the examine. A couple of exceptions embrace locations like Poland, the place electrical energy remains to be principally generated from burning coal.

Common lifetime emissions from electrical vehicles are as much as 70% decrease than gasoline vehicles in nations like Sweden and France (which get most of their electrical energy from renewable sources and nuclear energy), and round 30% decrease in the UK, based on the examine.

The researchers additionally famous that in a number of years, even inefficient electrical vehicles shall be produce fewer emissions general than most new gasoline vehicles in most nations, as a result of electrical energy era is predicted to change into much less carbon-intensive.

In 2050, each second automotive on the streets might be electrical, which would scale back international carbon dioxide emissions by as much as 1.5 gigatons per yr, which is equal to the full present emissions of Russia, the researchers projected.

“We have seen a number of dialogue about this not too long ago, with a lot of disinformation going round. Here’s a definitive examine that may dispel these myths,” Knobloch stated in a college information launch. “Even in our worst-case state of affairs, there can be a discount in emissions in virtually all circumstances.

“This perception must be very helpful for policymakers,” he added.

The examine was printed March 23 within the journal Nature Sustainability.

© 2020 HealthDay. All rights reserved.

Posted: March 2020

Information Medical Trials Gilead Sciences Assertion on Entry to Remdesivir Exterior of Medical Trials

March 22, 2020 — Gilead is working to quickly assess the security and efficacy of remdesivir as a possible remedy for COVID-19 by a number of ongoing scientific trials. Enrollment in scientific trials is the first strategy to entry remdesivir to generate vital knowledge that inform the suitable use of this investigational medication.

We acknowledge that there are severely unwell sufferers who’re unable to enroll in scientific trials and for whom no accredited remedy choices are efficient. Gilead has been working with regulatory companies to supply remdesivir to those sufferers the place possible. Thus far, we have now supplied emergency entry to remdesivir for a number of hundred sufferers in america, Europe and Japan.

In current weeks, there was an exponential improve in compassionate use requests for emergency entry to remdesivir, associated to the unfold of the coronavirus in Europe and america. This has flooded an emergency remedy entry system that was arrange for very restricted entry to investigational medicines and by no means supposed to be used in response to a pandemic.

To streamline the emergency entry course of, Gilead is presently within the technique of transitioning from particular person compassionate use requests to expanded entry applications. This method will each speed up entry to remdesivir for severely unwell sufferers and allow the gathering of information from all taking part sufferers. These applications are presently underneath speedy growth together with nationwide regulatory authorities worldwide, and should fluctuate by area primarily based on native legal guidelines and laws.

Throughout this transition interval, we’re unable to simply accept new particular person compassionate use requests as a result of an amazing demand during the last a number of days. We’re centered now on processing beforehand accredited requests and anticipate the expanded entry applications will provoke in the same anticipated timeframe that any new requests for compassionate use would have been processed. As an exception, compassionate use requests should be made for pregnant girls and kids lower than 18 years of age with confirmed COVID-19 and extreme manifestations of illness.

We acknowledge the pressing want and are working to implement expanded entry applications as rapidly as attainable, with the continued assist and collaboration of regulatory companies.
 

Posted: March 2020

Remdesivir FDA Approval Historical past

Extra Information Sources

Additional info

At all times seek the advice of your healthcare supplier to make sure the data displayed on this web page applies to your private circumstances.

Medical Disclaimer